Skip to main content

Table 4 Cost and proportion of patients for empiric use of Voriconazole vs. LAmB

From: Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey

Outcome

Voriconazole

LAmB

Proportion (%)

Cost (TL)

Proportionate cost (TL)*

Proportion (%)

Cost (TL)

Proportionate cost (TL)*

No baseline fungal infection

Successful treatment

24.58

11,551

2,839

29.62

19,492

5,774

Mortality

7.95

11,551

919

5.92

19,492

1,155

Breakthrough fungal infection

1.93

29,777

574

4.98

31,593

1,572

Premature discontinuation

9.88

30,179

2,982

6.64

29,784

1,976

Persistent fever

52.53

30,350

15,943

51.42

30,075

15,465

Baseline fungal infection

Successful treatment

1.45

11,551

167

0.95

25,832

245

Mortality

0.00

0

0

0.00

0

0

Persistent baseline fungal infection

1.69

24,400

412

0.47

36,207

172

Total

100.00

--

23,835

100.00

--

26,358

  1. *Individual costs may not sum to actual total as all figures are rounded to the nearest full Turkish Lira (TL).